TABLE 1

Demographic and clinical characteristics of 56 patients with a first episode of PCPa

ParameterHIV-infected patients (n = 46)Non-HIV-infected patients (n = 10)
WT DHPS genotypeMutant DHPS genotypePWT DHPS genotypeMutant DHPS genotypeP
Total patients24/46 (52)22/46 (48)5/10 (50)5/10 (50)
Mean age in yrs (SD)40 (12.2)40.1 (9.3)0.97748.5 (24.7)55.6 (23.3)0.671
No. male24/24 (100)21/22 (95)0.4682/5 (40)2/5 (40)1
New HIV diagnosis20/24 (83)18/22 (82)0.699NANA
Receipt of PCP prophylaxis0/24 (0)0/22 (0)10/50/5NA
Not receiving antiretroviral therapy24/24 (100)21/22 (96)0.478NANA
Fever15/24 (63)12/22 (55)0.7653/5 (60)2/3 (67)1
    Mean temp in °C (SD)38.1 (0.85)38.2 (0.98)0.786
Cough18/24 (75)19/22 (86)0.4643/5 (60)3/4 (75)1
Dyspnea21/24 (88)19/21 (91)14/5 (80)3/4 (75)1
Chest radiograph22/2421/225/55/5
    Abnormal21/22 (96)21/21 (100)15/5 (100)5/5 (100)
    Bilateral interstitial infiltrates18/22 (82)16/21 (76)1/5 (20)1/5 (20)NA
    Another pattern3/22 (14)b5/21 (24)c2/5 (40)d4/5 (80)e
    Not determined2/5 (40)
Thoracic CT scan15/2415/223/53/5
    Abnormal15/15 (100)15/15 (100)13/3 (100)3/3 (100)NA
        Ground-glass infiltrates12/15 (80)14/15 (93)1/3 (33)1/3 (33)
        Another pattern3/15 (20)f1/15 (7)g2/3 (67)h2/3 (67)i
Median CD4 cell count in cell/μl (IQR)27 (11–57.5)37 (18–64)0.465NDND
    No. of affected patients/total no.20/2419/22
Median serum albumin in g/liter (IQR)2.95 (2.37–3.40)2.90 (2.40–3.30)0.7943.15 (2.35–3.43)ND
    No. of affected patients/total no.18/2413/224/5
Median serum LDH in IU/liter (IQR)854.5 (568.8–1290)863 (665–1089)0.927875 (558,8–3210)1,099 (840–1405)0.730
    No. of affected patients/total no.22/2419/224/55/5
Mean hematocrit in % (SD)39.9 (6.39)36.8 (4.72)0.07630.1 (8.84)31.5 (9.54)0.782
    No. of affected patients/total no.23/2421/225/54/5
Median C-reactive protein in mg/liter (IQR)19.6 (4.8–99.9)8.5 (1.1–86.2)0.47573 (3.40–217.0)5,0 (1.90–50.25)0.191
    No. of affected patients/total no.18/2419/225/54/5
Other lung pathology2/24 (8)j1/22 (5)k13/5 (60)l1/5 (20)m0.524
  • a Values are expressed as the number of patients/total number of patients (%), except as stated otherwise in column 1. Abbreviations: DHPS, dyhydropteroate synthase; LDH, lactate dehydrogenase; IQR, interquartile range; n, total number of patients; NA, not applicable; ND, not determined.

  • b Bilateral interstitial infiltrates plus bilateral lobar consolidation (n = 1); bilateral interstitial infiltrates plus bilateral alveolar consolidation (n = 1); diffuse basal infiltrates (n = 1).

  • c Bilateral interstitial infiltrates plus air bronchogram and consolidation (n = 1); diffuse alveolar-interstitial pattern (n = 2); diffuse alveolar-interstitial pattern with apical cavitation (n = 1); right lobar consolidation (n = 1).

  • d Alveolar hemorrhage (n = 1); left pulmonary nodules (n = 1).

  • e Bilateral peribronchovascular thickening (n = 1); right basal consolidation (n = 1); bilateral alveolar consolidation plus air bronchogram (n = 1); right middle lobe consolidation (n = 1).

  • f Bilateral ground-glass infiltrates and bilateral consolidation (n = 1); noncharacteristic interstitial infiltrates (n = 1); diffuse infiltrates (n = 1).

  • g Bilateral ground-glass infiltrates and four cavitation-suggestive nodules (n = 1).

  • h Alveolar hemorrhage (n = 1); pneumomediastinum (n = 1).

  • i Bilateral ground-glass pattern and unilateral consolidation (n = 1); unilateral consolidation (n = 1).

  • j Bronchial asthma (n = 2).

  • k Mycobacterium tuberculosis.

  • l Dermatomyositis (n = 1); COPD plus cystic fibrosis (n = 1); bronchial asthma (n = 1).

  • m Myasthenia gravis.